Neuroantigen-specific, tolerogenic vaccines: GM-CSF is a fusion partner that facilitates tolerance rather than immunity to dominant self-epitopes of myelin in murine models of experimental autoimmune encephalomyelitis (EAE)

Table 4 The GMCSF-MOG TTV was a therapeutic treatment that blocked progression of actively-induced EAE

Treatment^a	Mean cum. score	Median cum. score	Mean maximal score	Median maximal score	% mean initial weight	Incidence of EAE^b	Mean # days with severe EAE^b
Saline	62.4 ± 17.3	69.0	3.6 ± 0.4	3.5	77.6%	8 of 8	18.6 ± 7.3
MOG35-55	32.4 ± 24.7	26.5	2.3 ± 1.3	2.5	88.9%	7 of 8	9.1 ± 9.0
GMCSF-MOG	3.4 ± 6.3	0.0	0.4 ± 0.7	0.0	88.9%	2 of 8	0.3 ± 0.7
TTV vs Saline	p < 0.001		p < 0.001		p = 0.004	p = 0.007	p < 0.001
TTV vs MOG35-55	p = 0.001		p = 0.004		ns	p = 0.041	p = 0.007
MOG35-55 vs saline	p = 0.024		p = 0.010		p = 0.004	ns	p = 0.036

^a Mice were immunized on day 0 with 200 ug MOG35-55 in CFA plus Pertussis toxin (200 ng i.p.) on days 0 and 2. Treatment was initiated when the first mice began showing clinical signs. Mice were matched for clinical signs and were injected subcutaneously with saline or 2 nanomoles of the synthetic peptide MOG35-55 or 2 nanomoles of the GMCSF-MOG TTV (in saline) on days 13, 15, 17, and 20. Mice were scored daily for clinical signs of EAE through day 38. Table 4 and Figure 8 represent the same experiment. Data were analyzed as described for Table 1.
^b Severe EAE was defined as a clinical score of 2.0 or greater.

ISSN: 1471-2172